Kairos Pharma adds NSCLC asset to portfolio

5 June 2026

US clinical-stage biotech Kairos Pharma (NYSE: KAPA), which is focused on innovative cancer therapeutics, has provided a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from chief executive Dr John Yu. The firm’s shares rose 4.8% to $0.48 on the announcement.

He noted that, “as we move toward the close of the second quarter, Kairos has been focused on adding some potentially impactful new development candidates to our existing pipeline. It announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK